Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ventyx Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VTYX
Nasdaq
8731
https://ventyxbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ventyx Biosciences Inc
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
- Mar 11th, 2024 11:00 am
NodThera says inflammation drug has positive effect in Parkinson’s
- Mar 7th, 2024 1:52 pm
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
- Mar 7th, 2024 1:00 pm
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- Mar 6th, 2024 1:00 pm
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
- Mar 4th, 2024 1:00 pm
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
- Feb 27th, 2024 9:01 pm
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
- Feb 22nd, 2024 12:00 pm
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 9:05 pm
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?
- Jan 28th, 2024 1:04 pm
Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares
- Dec 23rd, 2023 4:01 pm
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
- Nov 21st, 2023 9:05 pm
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
- Nov 10th, 2023 1:00 pm
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Nov 9th, 2023 9:01 pm
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
- Nov 9th, 2023 2:35 pm
Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment Flop
- Nov 7th, 2023 9:20 pm
Ventyx revises TYK2 drug plans after lackluster study data
- Nov 7th, 2023 12:00 pm
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
- Nov 6th, 2023 9:01 pm
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
- Nov 4th, 2023 4:16 pm
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
- Oct 11th, 2023 3:37 pm
Why Shares of Ventyx Biosciences Are Dropping Tuesday
- Oct 10th, 2023 4:55 pm
Scroll